Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Section for Cellular Therapy
5 publications found
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Breast Cancer Res, 21 (1), 9
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663